Cargando…

Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy

OBJECTIVE: Progressive pulmonary fibrosis (PPF) is the leading cause of death in systemic sclerosis (SSc). This study aimed to develop a clinical prediction nomogram using clinical and biological data to assess risk of PPF among patients receiving treatment of SSc‐related interstitial lung disease (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Volkmann, Elizabeth R., Wilhalme, Holly, Assassi, Shervin, Kim, Grace Hyun J., Goldin, Jonathan, Kuwana, Masataka, Tashkin, Donald P., Roth, Michael D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570669/ https://www.ncbi.nlm.nih.gov/pubmed/37592449 http://dx.doi.org/10.1002/acr2.11598

Ejemplares similares

Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease
por: Assassi, Shervin, et al.
Publicado: (2022)

Racial Disparities in Systemic Sclerosis: Short‐ and Long‐Term Outcomes Among African American Participants of SLS I and II
por: Volkmann, Elizabeth R., et al.
Publicado: (2020)

Early Radiographic Progression of Scleroderma: Lung Disease Predicts Long-term Mortality
por: Volkmann, Elizabeth R., et al.
Publicado: (2022)

Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit
por: Kakkar, Vishal, et al.
Publicado: (2022)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease
por: Volkmann, Elizabeth R., et al.
Publicado: (2016)

Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study
por: Assassi, Shervin, et al.
Publicado: (2022)

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
por: Khanna, Dinesh, et al.
Publicado: (2019)

Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
por: Volkmann, Elizabeth R., et al.
Publicado: (2020)

The Role of Type 1 Interferon in Systemic Sclerosis
por: Wu, Minghua, et al.
Publicado: (2013)

Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study
por: Mihai, Carina, et al.
Publicado: (2020)

Strategies for regulating tissue fibrosis and their clinical application
por: Kuwana, Masataka
Publicado: (2020)

Osteopontin in Systemic Sclerosis and its Role in Dermal Fibrosis
por: Wu, Minghua, et al.
Publicado: (2012)

Updates on genetics in systemic sclerosis
por: Ota, Yuko, et al.
Publicado: (2021)

Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need
por: Herrick, Ariane L., et al.
Publicado: (2022)

Predictors of progression in systemic sclerosis patients with interstitial lung disease
por: Distler, Oliver, et al.
Publicado: (2020)

The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis
por: Nuovo, Gerard J., et al.
Publicado: (2011)

Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
por: Khanna, Dinesh, et al.
Publicado: (2015)

Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management
por: Wells, Athol U.
Publicado: (2022)

Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases
por: Kuwana, Masataka, et al.
Publicado: (2022)

Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
por: Tashkin, Donald P
Publicado: (2020)

Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc
por: Bellocchi, Chiara, et al.
Publicado: (2023)

Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension
por: Furuya, Yoshiaki, et al.
Publicado: (2010)

Effect of genotype on the disease course in idiopathic pulmonary fibrosis despite antifibrotic treatment
por: Sterclova, Martina, et al.
Publicado: (2021)

Age of Initiating Smoking: An Independent Predictor of Chronic Obstructive Pulmonary Disease in Later Life
por: Tashkin, Donald P.
Publicado: (2023)

Transcriptional insights into pathogenesis of cutaneous systemic sclerosis using pathway driven meta-analysis assisted by machine learning methods
por: Xu, Xiao, et al.
Publicado: (2020)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
por: Shirai, Yuichiro, et al.
Publicado: (2021)

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2013)

An unusual association between focal segmental sclerosis and lupus nephritis: a distinct concept from lupus podocytopathy?
por: Hanaoka, Hironari, et al.
Publicado: (2014)

Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
por: Tashkin, Donald P, et al.
Publicado: (2018)

Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials
por: Kuwana, Masataka, et al.
Publicado: (2013)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Marijuana Use as a Risk Factor for Chronic Obstructive Pulmonary Disease: Not There Yet
por: Tashkin, Donald P., et al.
Publicado: (2023)

Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
por: Maher, Toby M, et al.
Publicado: (2023)

Outcomes and Prognostic Factors of Pulmonary Hypertension Patients Undergoing Emergent Endotracheal Intubation
por: Hong, Andrew W., et al.
Publicado: (2022)

Defining Disease Modification in Chronic Obstructive Pulmonary Disease
por: Halpin, David M.G., et al.
Publicado: (2009)

Immunomodulatory Effects of Exercise in Experimental Multiple Sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2019)

Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis
por: Yamaguchi, Yukie, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_pgmi56rkc66e1b684s63ljtv6s